S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
NASDAQ:BNTX

BioNTech (BNTX) Stock Price, News & Analysis

$86.48
-0.53 (-0.61%)
(As of 04/12/2024 ET)
Today's Range
$85.60
$86.79
50-Day Range
$86.48
$96.30
52-Week Range
$85.21
$131.52
Volume
726,723 shs
Average Volume
605,821 shs
Market Capitalization
$20.56 billion
P/E Ratio
20.99
Dividend Yield
N/A
Price Target
$120.40

BioNTech MarketRank™ Stock Analysis

Analyst Rating
Hold
2.30 Rating Score
Upside/​Downside
39.2% Upside
$120.40 Price Target
Short Interest
Bearish
1.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.70mentions of BioNTech in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.98) to ($1.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.22 out of 5 stars

Medical Sector

281st out of 923 stocks

Biological Products, Except Diagnostic Industry

40th out of 155 stocks

BNTX stock logo

About BioNTech Stock (NASDAQ:BNTX)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

BNTX Stock Price History

BNTX Stock News Headlines

The 3 Best Bargain Stocks to Buy in Q2 2024
My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
BioNTech Full Year 2023 Earnings: Misses Expectations
My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
BioNTech Q4 Net Profit Plummets
Earnings Outlook For BioNTech
See More Headlines
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
4/13/2024
Next Earnings (Confirmed)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BNTX
Employees
6,133
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$120.40
High Stock Price Target
$171.00
Low Stock Price Target
$90.00
Potential Upside/Downside
+39.2%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$1.01 billion
Pretax Margin
31.06%

Debt

Sales & Book Value

Annual Sales
$3.82 billion
Cash Flow
$4.94 per share
Book Value
$92.17 per share

Miscellaneous

Free Float
192,083,000
Market Cap
$20.56 billion
Optionable
Optionable
Beta
0.23

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Ugur Sahin M.D. (Age 59)
    Co-Founder, CEO & Chair of the Management Board
    Comp: $1.25M
  • Dr. Ozlem Tureci M.D. (Age 57)
    Co-Founder, Chief Medical Officer & Member of Management Board
    Comp: $822.13k
  • Mr. Jens H. Holstein (Age 61)
    CFO & Member of Management Board
    Comp: $1.44M
  • Dr. Sierk Poetting Ph.D. (Age 51)
    MD, COO & Member of Management Board
    Comp: $844.88k
  • Mr. Ryan Richardson (Age 45)
    Chief Strategy Officer, MD & Member of Management Board
    Comp: $1.04M
  • Mr. Sean Marett (Age 59)
    Chief Business Officer, Chief Commercial Officer & Member of Management Board
    Comp: $815.63k
  • Dr. James Timothy Patrick Ryan Ph.D. (Age 49)
    Chief Legal Officer & Member of the Management Board
    Comp: $610.91k
  • Mr. Zach Taylor
    Senior Vice President of Corporate Development & Strategy
  • Dr. Katalin Kariko Ph.D.
    Senior VP & External Consultant for RNA Protein Replacement Therapies
  • Dr. Oliver Henning Ph.D.
    Senior Vice President of Operations

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in BioNTech SE:

  • BioNTech SE is actively developing a range of innovative immunotherapies for cancer and infectious diseases, showcasing a strong pipeline of product candidates.
  • The company's FixVac product candidates, such as BNT122 in Phase II clinical trials for first-line melanoma and multiple solid tumors, demonstrate promising potential in addressing unmet medical needs.
  • BioNTech SE has established collaborations with reputable partners like Genentech, Pfizer, and Sanofi, enhancing its research capabilities and market reach.
  • With ongoing clinical trials for various cancers like prostate, ovarian, and lung cancer, BioNTech SE is positioned to make significant advancements in cancer treatment, potentially leading to increased market value.
  • Considering the current stock price and the company's robust development pipeline, investing in BioNTech SE could offer long-term growth opportunities for investors.

Cons

Investors should be bearish about investing in BioNTech SE for these reasons:

  • Despite the promising pipeline, the biotechnology industry is highly competitive and subject to regulatory challenges, which could impact the company's ability to bring products to market successfully.
  • Ongoing clinical trials carry inherent risks, including potential setbacks or failures, which could lead to delays in product approvals and revenue generation.
  • The success of BioNTech SE's product candidates is not guaranteed, and any setbacks in clinical trials or regulatory approvals could negatively affect the company's financial performance and stock value.
  • Investing in biotechnology companies like BioNTech SE involves high volatility due to market sentiment, regulatory changes, and scientific uncertainties, which may not align with all investors' risk tolerance levels.
  • While the company has collaborations with industry leaders, partnership dynamics and outcomes are subject to change, impacting BioNTech SE's research priorities and market positioning.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BNTX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioNTech stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.
View BNTX analyst ratings
or view top-rated stocks.

What is BioNTech's stock price target for 2024?

10 Wall Street analysts have issued 1-year price targets for BioNTech's shares. Their BNTX share price targets range from $90.00 to $171.00. On average, they anticipate the company's stock price to reach $120.40 in the next twelve months. This suggests a possible upside of 39.2% from the stock's current price.
View analysts price targets for BNTX
or view top-rated stocks among Wall Street analysts.

How have BNTX shares performed in 2024?

BioNTech's stock was trading at $105.54 at the beginning of the year. Since then, BNTX stock has decreased by 18.1% and is now trading at $86.48.
View the best growth stocks for 2024 here
.

When is BioNTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our BNTX earnings forecast
.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) posted its earnings results on Wednesday, March, 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by $0.59. The firm earned $1.59 billion during the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a trailing twelve-month return on equity of 4.60% and a net margin of 24.26%.

What is Ugur Sahin's approval rating as BioNTech's CEO?

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

When did BioNTech IPO?

BioNTech (BNTX) raised $251 million in an IPO on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

Who are BioNTech's major shareholders?

BioNTech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include IMC Chicago LLC (0.00%), Green Alpha Advisors LLC (0.00%), Park Avenue Securities LLC (0.00%), American National Bank (0.00%) and GAMMA Investing LLC (0.00%).

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does BioNTech have any subsidiaries?
The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.
Read More
This page (NASDAQ:BNTX) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners